Briacell Therapeutics Other Stockholder Equity Over Time
| BCTX Stock | USD 0.66 0.44 40.00% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Briacell Therapeutics Performance and Briacell Therapeutics Correlation. Briacell |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Briacell Therapeutics. If investors know Briacell will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Briacell Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.29) | Return On Assets (1.26) | Return On Equity (2.06) |
The market value of Briacell Therapeutics is measured differently than its book value, which is the value of Briacell that is recorded on the company's balance sheet. Investors also form their own opinion of Briacell Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Briacell Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Briacell Therapeutics' market value can be influenced by many factors that don't directly affect Briacell Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Briacell Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Briacell Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Briacell Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Other Stockholder Equity Analysis
Compare Briacell Therapeutics and related stocks such as X4 Pharmaceuticals, Terns Pharmaceuticals, and Day One Biopharmaceu Other Stockholder Equity Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| XFOR | 372 K | 372 K | 372 K | 372 K | 372 K | 372 K | 991 K | 69.6 M | 156.6 M | 100.7 M | 267.1 M | 347.4 M | 450.8 M | 529 M | 555.4 M |
| TERN | 455 K | 455 K | 455 K | 455 K | 455 K | 455 K | 455 K | 455 K | 455 K | 1.2 M | 14.6 M | 342.7 M | 520.2 M | 588 M | 617.4 M |
| DAWN | (5.4 M) | (5.4 M) | (5.4 M) | (5.4 M) | (5.4 M) | (5.4 M) | (5.4 M) | (5.4 M) | (5.4 M) | (5.4 M) | 92.6 M | 408.6 M | 601.8 M | 805.1 M | 418.6 M |
| PDSB | 693.5 K | 693.5 K | 693.5 K | 693.5 K | 2 M | 184.8 M | 190.5 M | 214.6 M | 223.1 M | 40.6 M | 70.9 M | 123.9 M | 145.6 M | 170.6 M | 136.7 M |
| INZY | 1.1 M | 1.1 M | 1.1 M | 1.1 M | 1.1 M | 1.1 M | 1.1 M | 1.1 M | 1.1 M | (76.5 M) | 79.8 M | 256.9 M | 333.4 M | 426.4 M | 447.7 M |
| ELEV | (7.2 M) | (7.2 M) | (7.2 M) | (7.2 M) | (7.2 M) | (7.2 M) | (7.2 M) | (7.2 M) | (7.2 M) | (7.2 M) | (97.1 M) | 46.4 M | 199.5 M | 250.8 M | 263.3 M |
| MREO | 113.7 M | 113.7 M | 113.7 M | 113.7 M | 113.7 M | 113.7 M | 100 M | 118.2 M | 118.2 M | 138.7 M | 294.7 M | 383.2 M | 488.1 M | 484.9 M | 273.7 M |
| HEPA | (900) | (900) | (900) | 2.5 M | 2.5 M | 17.4 M | 32.2 M | 67.5 M | 76.7 M | 97.7 M | 142.9 M | 224.8 M | 223.9 M | 230.3 M | 241.8 M |
| HOOK | 2.5 M | 2.5 M | 2.5 M | 2.5 M | 2.5 M | 2.5 M | 2.5 M | 2.5 M | 108.1 M | 81.8 M | 309.3 M | 317.1 M | 397.3 M | 467 M | 264.5 M |
Briacell Therapeutics and related stocks such as X4 Pharmaceuticals, Terns Pharmaceuticals, and Day One Biopharmaceu Other Stockholder Equity description
My Equities
My Current Equities and Potential Positions
| Briacell Therapeutics Corp | BCTX |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Location | British Columbia; Canada |
| Exchange | NASDAQ Exchange |
USD 0.66
Additional Tools for Briacell Stock Analysis
When running Briacell Therapeutics' price analysis, check to measure Briacell Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Briacell Therapeutics is operating at the current time. Most of Briacell Therapeutics' value examination focuses on studying past and present price action to predict the probability of Briacell Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Briacell Therapeutics' price. Additionally, you may evaluate how the addition of Briacell Therapeutics to your portfolios can decrease your overall portfolio volatility.